Publications

Our Webinars

Discovery of Novel DHFR Inhibitors

The webinar reviews the story of discovery of novel human DHFR inhibitors, presented by Professor Dennis Wright of University of Connecticut. UCP1162 is a structurally novel anti-folate that can evade cellular resistance. UCP1162 inhibits the human DHFR with affinity and kinetics comparable to methotrexate (MTX) and demonstrated promising mechanistic properties in reducing acute inflammation. We likewise demonstrate the pivotal role Micro-Tag™ cell target engagement played in discovery of novel DHFR Inhibitors.

Novel Druggable Targets - Inhibitors of TBL1 from Discovery to Clinic

Stephen Horrigan PhD, CSO @ Iterion Therapeutics, a clinical-stage biotech company, is reviewing the drug discovery story of inhibitors for TBL1 (Transducin beta-like protein 1). TBL1 is a high-value challenging therapeutic target involved in a number of essential cellular functions. Stephen is dissecting the TBL1 story from discovery to clinic. Elmar Nurmemmedov PhD, Cofounder @ CellarisBio, is covering the importance of Micro-Tag™ cell target engagement technology in de-risking and accelerating the TBL1 program.

Predictive Drug Discovery Empowered with Cell Target Engagement

Here we bring together the two major elements in early drug discovery: Target engagement in silico & Target engagement in cell.
Eric Sigel, CEO @ Citadel Discovery, we will dissect the fundamentals of predictive drug discovery and DEL / ML to fuel therapeutic pipelines focused on challenging drug targets. Ivan Babic, Cofounder @ CellarisBio, will dissect the importance of pairing predictive drug discovery with live cell systems.

Target Engagement in Early Drug Discovery

This webinar provides insight into practices of target discovery & validation together with importance of target engagement in designing winning drug discovery programs. Starred by Dr Christopher Miller, ex-head genomics research center at Abbvie and ex-VP of functional genomics at GSK, we dissect the success of target discovery and validation through functional genomics. Dr Miller also ties into the importance of target engagement early in drug discovery.

Discovery of Pan-KRAS Inhibitors with Robust Anti-Tumor Activity

In this webinar we review the discovery of potent pan-KRAS inhibitors for gastrointestinal and pancreatic cancers. Led by legendary Professor Gary A. Piazza of Auburn University, the story will delve into layers of target biology, mechanism of action of the novel KRAS inhibitors, together with the preclinical data.

Paradigm of Cell Target Engagement

The webinar will review the fundamentals of cell target engagement and its importance in early drug discovery. It provides a short comparative synopsis of conventional biophysical methods (such as SPR, MST, DSF etc) that require purified and well structured and functional recombinant proteins. It also provides a review of cell target engagement methods together with enzyme complementation technologies.

Next-Gen Cell Target Engagement

AACR Poster 2024

Our Webinars

Discovery of Novel DHFR Inhibitors

Novel Druggable Targets - Inhibitors of TBL1 from Discovery to Clinic

Predictive Drug Discovery Empowered with Cell Target Engagement

Target Engagement in Early Drug Discovery

Discovery of Pan-KRAS Inhibitors with Robust Anti-Tumor Activity

Paradigm of Cell Target Engagement

Our BloG

Next-Gen Cell Target Engagement

AACR Poster 2024

Our Webinars

Discovery of Novel DHFR Inhibitors

Novel Druggable Targets - Inhibitors of TBL1 from Discovery to Clinic

Predictive Drug Discovery Empowered with Cell Target Engagement

Target Engagement in Early Drug Discovery

Discovery of Pan-KRAS Inhibitors with Robust Anti-Tumor Activity

Paradigm of Cell Target Engagement

Our BloG

This website uses cookies.